Bengal Physician Journal

Register      Login

VOLUME 7 , ISSUE 2 ( May-August, 2020 ) > List of Articles

REVIEW ARTICLE

Management of Hyperglycemia in In-hospital COVID-19 Patients: A Review

Shreyashi Dasgupta, Shashank R Joshi

Keywords : COVID-19, Diabetes, Hypoglycemia, Insulin

Citation Information : Dasgupta S, Joshi SR. Management of Hyperglycemia in In-hospital COVID-19 Patients: A Review. Bengal Physician Journal 2020; 7 (2):31-34.

DOI: 10.5005/jp-journals-10070-7027

License: CC BY-NC 4.0

Published Online: 01-08-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The current coronavirus-19 (COVID-19) pandemic has diverted the world\'s attention to the burning problem of infectious diseases and their management. Clinicians are increasingly realizing that the management of diseases like COVID-19 requires not only antimicrobial drugs but also drugs or strategies to tackle the various comorbidities occurring or aggravating due to the disease. Hypoglycemia is one of the important adverse effects of hydroxychloroquine, used frequently in COVID-19. The known diabetics affected with COVID-19 are therefore at a greater risk of hypoglycemia. In this review article, we describe the management strategy for the known diabetics infected with COVID-19 and admitted in inpatient settings, including the dose calculations for insulin infusion and subcutaneous administration of insulin.


PDF Share
  1. CDC. Antibiotic/antimicrobial resistance (AR/AMR), 2019.
  2. Song Z, Xu Y, Bao L, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019;11(1):59. DOI: 10.3390/v11010059.
  3. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323(18):1775–1776. DOI: 10.1001/jama.2020.4683.
  4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. J Am Med Assoc 2020;323(13):1239–1242. DOI: 10.1001/jama.2020.2648.
  5. Lorenzo-González C, Atienza-Sánchez E, Reyes-Umpierrez D, et al. Safety and efficacy of dpp4-inhibitors for management of hospitalized general medicine and surgery patients with type 2 diabetes. Endocr Pract 2020. Online ahead of print. DOI: 10.4158/EP-2019-0481.
  6. Vora KA, Porter G, Peng R, et al. Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol 2009;10:19. DOI: 10.1186/1471-2172-10-19.
  7. Viby NE, Isidor MS, Buggeskov KB, et al. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology 2013;154(12):4503–4511. DOI: 10.1210/en.2013-1666.
  8. Toki S, Goleniewska K, Reiss S, et al. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol 2018;142(5):1515–1528. DOI: 10.1016/j.jaci.2017.11.043.
  9. Zhou F, Zhang Y, Chen J, et al. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 2016;791:735–740. DOI: 10.1016/j.ejphar.2016.10.016.
  10. Bloodworth MH, Rusznak M, Pfister CC, et al. Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol 2018;142:683–687. DOI: 10.1016/j.jaci.2018.01.053.
  11. Fayfman M, Galindo RJ, Rubin DJ, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care 2019;42(3):450–456. DOI: 10.2337/dc18-1760.
  12. Lee MY, Fraser JD, Chapman MJ, et al. The effect of exogenous glucose dependent insulinotropic polypeptide in combination with glucagon-like peptide1 on glycemia in the critically ill. Diabetes Care 2013;36(10):3333–3336. DOI: 10.2337/dc13-0307.
  13. Pasquel FJ, Fayfman M, Umpierrez GE. Debate on insulin vs non-insulin use in the hospital setting-is it time to revise the guidelines for the management of inpatient diabetes? Curr Diab Rep 2019;19(9):65. DOI: 10.1007/s11892-019-1184-8.
  14. American Diabetes Association. Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008;31(3):596–615. DOI: 10.2337/dc08-9017.
  15. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87(3):978. DOI: 10.1210/jcem.87.3.8341.
  16. Kathleen MD, Braithwaite SS, Preiser J-C, et al. Stress hyperglycaemia. Lancet 2009;373(9677):1798–1807. DOI: 10.1016/S0140-6736(09)60553-5
  17. American Diabetes Association. Standards of medical care in diabetes 2018. Diabetes Care 2018;36(Suppl 1):S11–S66. DOI: 10.2337/dc13-S011.
  18. Singh BSJ, Baruah Manash P, Sanjay K, et al. Review article: Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care. J Anaesthesiol Clin Pharmacol 2015;31(2):155–164. DOI: 10.4103/0970-9185.155141.
  19. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am 2012;41(1):175–201. DOI: 10.1016/j.ecl.2012.01.001.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.